CAPSTONE THERAPEUTICS CORP (CAPS)

Overview Price 0.17 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank N/A - N/A Open Price $0.16 Previous Close $0.17 Daily Range $0.16 - $0.17 52-Week Range $0.16 - $0.40 Volume 1,312 Capstone Therapeutics Corp., formerly known as OrthoLogic Corp., is a biotechnology company focused on developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is engaged in the development and commercialization of two product platforms: AZX100 and Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, a class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin, the Company's novel synthetic 23-amino acid peptide, stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction. Capstone Therapeutics Corp. is headquartered in Tempe, Arizona. Other Resources for CAPS Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary No Commentary Found for This Ticker. Capstone Therapeutics Corp., formerly known as OrthoLogic Corp., is a biotechnology company focused on developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is engaged in the development and commercialization of two product platforms: AZX100 and Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, a class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin, the Company's novel synthetic 23-amino acid peptide, stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction. Capstone Therapeutics Corp. is headquartered in Tempe, Arizona.   No brokerage coverage for CAPS   CAPS Ratings: BUY  SELL  HOLD CAPS Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 0 Buy 0 Sell   Top Buy Analysis No Buy Analysis. Be the First. More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	11/25/11	Regeneron Seeks Label Expansion - Analyst Blog	0
Zacks_Analysts	0.00	11/09/11	Novartis' ACZ885 Meets Study Goal - Analyst Blog	0
Zacks_Analysts	0.00	10/25/11	Novartis Misses, Plans Job Cuts - Analyst Blog	0
Zacks_Analysts	0.00	10/05/11	Two Novartis Drugs Cleared in Japan - Analyst Blog	0
Zacks_Analysts	0.00	09/22/11	Novartis Unveils Upbeat ACZ885 Data - Analyst Blog	0
Zacks_Analysts	0.00	08/31/11	Pipeline Setback for Novartis - Analyst Blog	0
Zacks_Analysts	0.00	06/22/11	FDA Panel Votes Down NVS Drug - Analyst Blog	0
Zacks_Analysts	0.00	06/09/11	Regeneron Keep - Analyst Blog	0
Zacks_Analysts	0.00	05/26/11	Novartis Cites Positive Gout Data - Analyst Blog	0
Zacks_Analysts	0.00	03/09/11	Regeneron Keeps Neutral Rec - Analyst Blog	0

Pages: [ 1 ]  2  >>

Commentary

There are no open picks with this stock at the moment.

Picks

There are no open picks with this stock at the moment.